Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-directed CAR-T cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-directed CAR-T cells developed by the Chinese PLA General Hospital are an investigational allogeneic (donor-derived) chimeric antigen receptor T-cell therapy. This specific treatment is being evaluated in Phase I clinical trials for patients with relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. The therapy involves engineering T cells from a healthy donor to express a CAR targeting the CD19 antigen, which is widely expressed on B-cell lineage cells. In the clinical protocol described, these CAR-T cells are administered prior to a donor-derived hematopoietic stem cell transplant (HSCT) to eradicate residual disease and potentially enhance the graft-versus-leukemia (GVL) effect while minimizing the risk of CD19-negative relapse.
- Other names
- Donor-derived CD19-directed CAR-T cellsAllo-CD19-CAR-T cellsAllo-CD-19-CAR-T cellsAllo-CD 19-CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19-directed CAR-T cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-directed CAR-T cells (Chinese PLA General Hospital).